KIRKLAND, QC, Oct. 1, 2018 /CNW Telbec/ - Manitex Capital
Inc. ("Manitex") (TSXV: MNX) is pleased to announce that its
affiliate, Valeo Pharma Inc. ("Valeo Pharma"), has filed a
non-offering preliminary prospectus with the securities regulatory
authorities of all provinces and territories in Canada.
The non-offering prospectus is being filed for the purpose of
allowing Valeo Pharma to become a reporting issuer in all
jurisdictions of Canada and to
become eligible for listing pursuant to the policies of the TSX
Venture Exchange ("TSXV"). Listing will be subject to Valeo Pharma
fulfilling all of the listing requirements of the TSXV.
The preliminary prospectus can be found on SEDAR at
www.sedar.com.
Caution regarding forward-looking statements
This news release may contain certain forward-looking statements
regarding the Corporation's expectations for future events. Such
expectations are based on certain assumptions that are founded on
currently available information. If these assumptions prove
incorrect, actual results may differ materially from those
contemplated by the forward-looking statements contained in this
press release. Factors that could cause actual results to differ
include, amongst others, uncertainty as to the final result and
other risks. The Corporation disclaims any intention or obligation
to publicly update or revise any forward- looking statements,
whether as a result of new information, future events or otherwise,
other than as required by security laws.
About Manitex Capital Inc.
Manitex Capital Inc. invests in promising emerging companies
from diversified sectors including life sciences, cleantech and
sustainable products/technologies. Manitex provides its portfolio
companies with specialized corporate finance and advisory services
including corporate strategy, mergers and acquisitions, public
markets access and financing. Manitex currently has 12,561,276
common shares outstanding which are quoted for trading on the TSX
Venture Exchange, symbol MNX.V.
About Valeo Pharma Inc.
Valeo Pharma is a specialty pharmaceutical company dedicated to
the acquisition, in-licensing and launch of innovative prescription
products in Canada. With a focus on neurodegenerative
diseases, woman's health and rare diseases, Valeo Pharma has a
growing portfolio of innovative products and a platform to properly
manage these products through all stages of
commercialization. Headquartered in Kirkland,
Quebec, Valeo Pharma has all
capabilities internally to register and market health care
solutions for Canadian patients. For more information, please
visit www.valeopharma.com.
TSX Venture Exchange nor its Regulation Services Provider (as
that termis defined in the policies of the TSX Venture Exchange)
accept responsibility for the adequacy or accuracy of this
release.
SOURCE Manitex Capital Inc.
